(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Your guide to how to safely thaw and cook your Thanksgiving turkey this year, according to experts - 2Judge sets $60K bond for Florida congresswoman accused of stealing $5M in COVID-19 funds
- 3Figure out How to Introduce Sunlight powered chargers on Your Rooftop securely
- 4Find the Advantages of Deep rooted Getting the hang of: Extending Information and Self-awareness
- 5How did birds survive while dinosaurs went extinct?
- Manual for 10 Scrumptious Specialty Mixed drinks
- Scientists find evidence that an asteroid contains tryptophan
- Report: Thailand strikes deal with Iran for safe passage of Hormuz
- Two Indonesian UN peacekeepers killed in explosion in Lebanon
- the Wild in Style: The Reduced Portage Mustang's Bold Heritage
- 3 Italian City Cars That Outsmarted Regulations and Rivals
- Health insurance premiums rose nearly 3x the rate of worker earnings over the past 25 years
- Figure out How to Keep up with Oral Wellbeing During Pregnancy
- SpaceX launches Starlink satellites on its 150th Falcon 9 mission of the year
